Research Plan for Early Disease Screening Biomarkers in Healthy Individuals

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07569094

Enrollment

300

Registered

2026-05-06

Start date

2026-05-01

Completion date

2027-12-01

Last updated

2026-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health

Keywords

health

Brief summary

The establishment of reference intervals for biomarkers in healthy populations relies on large-scale, standardized cohort data. However, current baseline data for hematology, liver and kidney function, and multi-omics (genomics, transcriptomics, proteomics, and metabolomics) in Chinese healthy populations are constrained by significant regional disparities and insufficient sample sizes, limiting the development of early disease screening markers. To address these challenges, this study aims to: (1) establish a comprehensive database for hematology and liver/kidney function indicators; (2) construct a multi-omics database using blood and sputum samples; and (3) explore the correlations among multi-omics indicators and their associations with demographic characteristics.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

1. Age: 18 - 65 years old, gender not restricted; 2. No clear history of chronic diseases (hypertension, diabetes, cardiovascular and cerebrovascular diseases, chronic liver and kidney diseases, tumors, etc.); 3. No infection history in the past 3 months (fever, cough, sore throat, etc.); 4. No use of antibiotics, hormones, immunosuppressants, etc. within the past 1 month; 5. Voluntarily sign the informed consent form and cooperate to complete the follow-up.

Exclusion criteria

1. Abnormal laboratory indicators (ALT/AST \> 2 times the upper limit of normal value, Cr \> upper limit of normal value, main indicators of blood routine test are abnormal and have clinical significance); 2. Pregnant or lactating women; 3. Recent (within 3 months) history of surgery, trauma or blood transfusion; 4. Mental illness or cognitive impairment that makes it impossible to cooperate with the research.

Design outcomes

Primary

Measure	Time frame
Blood routine test	At the time of enrollment

Secondary

Measure	Time frame
Liver function	At the time of enrollment
renal function	At the time of enrollment

Countries

China

Contacts

CONTACTLiang Peng, Doctor

pl_206@126.com86-020-85959142

STUDY_DIRECTORZifeng Yang

The First Affiliated Hospital of Guangzhou Medical University

Outcome results